Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,187,813

« Back to Dashboard

Details for Patent: 6,187,813

Title: Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
Abstract:The invention relates to ophthalmological compositions for topical treatment of glaucoma or ocular hypertension comprising an effective intraocular pressure reducing amount of a prostaglandin derivative of PGA, PGB, PGD, PGE or PGF, in which the omega chain contains a ring structure, in an ophthalmologically compatible carrier. The invention further relates to the preparation of said compositions and their use for treatment of glaucoma or ocular hypertension.
Inventor(s): Stjernschantz; Johan Wilhelm (Uppsala, SE), Resul; Bahram (Uppsala, SE)
Assignee: Pharmacia & Upjohn Aktiebolag (Stockholm, SE)
Filing Date:May 10, 1999
Application Number:09/307,813
Claims:1. A therapeutic composition for topical treatment of ocular hypertension containing a prostaglandin PGF in an amount sufficient to reduce intraocular pressure without causing substantial intraocular irritation, and an ophthamologically compatible vehicle, in which the alpha chain of the prostaglandin comprises a chain having the structure

CH.sub.2 --CH.dbd.CH--CH.sub.2 --CH.sub.2 --CH.sub.2 --COOR.sub.1, wherein R.sub.1 is an alkyl group, and in which the omega chain of the prostaglandin has the formula


C is a carbon atom (the number according to standard prostaglandin nomenclature being indicated by the subscript);

B is a single bond, double bond or triple bond;

D is a subchain of 2-5 carbon atoms and 1-2 heteroatoms selected from the group consisting of O, N and S, having a substituent on each carbon atom selected from the group consisting of a hydrogen atom, an alkyl group, oxo group and a hydroxyl group; and

R.sub.2 is a phenyl group substituted with a trifluoromethyl group.

2. The therapeutic composition according to claim 1 wherein R.sub.1 is a butyl group.

3. The therapeutic composition according to claim 1 wherein the prostaglandin is a PGF.sub.2-alpha.

4. The therapeutic composition according to claim 2 wherein the prostaglandin is a PGF.sub.2-alpha.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.